These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 18066033)

  • 21. Health purveyors that look hale.
    McFadden M
    Fortune; 1986 May; 113(11):147-8, 150. PubMed ID: 10276676
    [No Abstract]   [Full Text] [Related]  

  • 22. Polio endgame. Wanted: drug for a disappearing disease.
    Enserink M
    Science; 2004 Mar; 303(5666):1971. PubMed ID: 15044783
    [No Abstract]   [Full Text] [Related]  

  • 23. Deal watch: AbbVie invests in pioneering celiac disease therapy.
    Crunkhorn S
    Nat Rev Drug Discov; 2013 Jul; 12(7):497. PubMed ID: 23812262
    [No Abstract]   [Full Text] [Related]  

  • 24. Biotech slumps in Q1.
    Lawrence S
    Nat Biotechnol; 2008 May; 26(5):486. PubMed ID: 18464769
    [No Abstract]   [Full Text] [Related]  

  • 25. Can Merck stand alone?
    Warner M
    Fortune; 2001 Jul; 144(2):62. PubMed ID: 11471356
    [No Abstract]   [Full Text] [Related]  

  • 26. A rollercoaster ride.
    Jacobs T
    Nat Biotechnol; 2006 Mar; 24(3):284. PubMed ID: 16525390
    [No Abstract]   [Full Text] [Related]  

  • 27. A new prescription for your portfolio.
    Clifford L; O'Keefe B; Stires D
    Fortune; 2001 Jul; 144(2):74-6, 78, 80. PubMed ID: 11471357
    [No Abstract]   [Full Text] [Related]  

  • 28. Investigating investment in biopharmaceutical R&D.
    Carter PH; Berndt ER; DiMasi JA; Trusheim M
    Nat Rev Drug Discov; 2016 Oct; 15(10):673-4. PubMed ID: 27616295
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 'The future of cancer treatment'.
    O'Keefe B
    Fortune; 2001 Jul; 144(2):80. PubMed ID: 11471358
    [No Abstract]   [Full Text] [Related]  

  • 30. Drug firms' woes may slow profit growth.
    Dine DD
    Mod Healthc; 1989 Feb; 19(7):52. PubMed ID: 10291927
    [No Abstract]   [Full Text] [Related]  

  • 31. Deal watch: Merck invests in pioneering cytomegalovirus programme.
    Crunkhorn S
    Nat Rev Drug Discov; 2012 Dec; 11(12):896. PubMed ID: 23197025
    [No Abstract]   [Full Text] [Related]  

  • 32. Investors explore buying technology data.
    Morrissey J
    Mod Healthc; 1996 Jan; 26(3):19. PubMed ID: 10153971
    [No Abstract]   [Full Text] [Related]  

  • 33. Pharmas partner in venture seeking drug discovery tools.
    Mack GS
    Nat Biotechnol; 2008 Sep; 26(9):960-1. PubMed ID: 18779790
    [No Abstract]   [Full Text] [Related]  

  • 34. Antibiotics: a shot in the arm.
    Leeb M
    Nature; 2004 Oct; 431(7011):892-3. PubMed ID: 15496888
    [No Abstract]   [Full Text] [Related]  

  • 35. Just say grow. Cardinal Health looks beyond drug distribution and sees a healthy future.
    Speer TL
    Hosp Health Netw; 1996 Aug; 70(15):34-5. PubMed ID: 8704771
    [No Abstract]   [Full Text] [Related]  

  • 36. The new world disorder.
    Stires D
    Fortune; 2002 Dec; 146(12):62-4, 68, 70 passim. PubMed ID: 12500480
    [No Abstract]   [Full Text] [Related]  

  • 37. Merck's man in the hot seat.
    Simons J
    Fortune; 2004 Feb; 149(4):111-2, 114. PubMed ID: 14983668
    [No Abstract]   [Full Text] [Related]  

  • 38. Trends in biopharmaceutical IPOS: 1996-2005.
    Williams DR; Young CC
    J Health Care Finance; 2006; 33(2):39-54. PubMed ID: 19175239
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharma consolidates its grip on post-antibody landscape.
    Sheridan C
    Nat Biotechnol; 2007 Apr; 25(4):365-6. PubMed ID: 17420728
    [No Abstract]   [Full Text] [Related]  

  • 40. Socio-economic impact of antiviral intervention.
    Flessa S; Marschall P
    Handb Exp Pharmacol; 2009; (189):347-74. PubMed ID: 19048207
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.